In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjogren's syndrome
In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjogren's syndrome
复制标题
DOI：
10.1093/rheumatology/keu292
复制
发表时间：
2015-01-01
期刊：
影响因子：
5.5
通讯作者：
Calafiore, Riccardo
中科院分区：
文献类型：
--
作者：
Alunno, Alessia;Montanucci, Pia;Calafiore, Riccardo
方法.选择10例pSS患者和10例健康供体。从静脉血获得外周血单核细胞（PBMC）以建立与CpS-hUCMS的共培养物。流式细胞仪检测淋巴细胞增殖和表型，实时荧光定量PCR检测IFN-γ预处理的hUCMS。我们发现CpS-hUCMS抑制pSS T细胞增殖并恢复Treg/Th 17比率，从而可能对pSS疾病进程产生积极影响。我们已经开发了一种新的生物杂交药物输送系统，现在等待在自身免疫性疾病，包括pSS的临床应用。
Methods. Ten pSS patients and 10 healthy donors were selected. Peripheral blood mononuclear cells (PBMCs) were obtained from venous blood to establish co-cultures with CpS-hUCMS. Lymphocyte proliferation and phenotypic analysis was performed by flow cytometry and real-time PCR on IFN-gamma-pretreated hUCMS was performed before PBMCs co-culture.Results. We found that CpS-hUCMS suppress pSS T cell proliferation and restore the Treg/Th17 ratio, thereby possibly positively impacting the pSS disease process.Conclusion. We have developed a new biohybrid drug delivery system that now waits for clinical application in autoimmune diseases, including pSS.